C
Christine Fritsch
Researcher at Novartis
Publications - 54
Citations - 3784
Christine Fritsch is an academic researcher from Novartis. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Cancer. The author has an hindex of 18, co-authored 52 publications receiving 3438 citations.
Papers
More filters
Journal ArticleDOI
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira,Frédéric Stauffer,Josef Brueggen,Pascal Furet,Christian Schnell,Christine Fritsch,Saskia M. Brachmann,Patrick Chène,Alain De Pover,Kevin Schoemaker,Doriano Fabbro,Daniela Gabriel,Marjo Simonen,Leon Murphy,Peter Finan,William R. Sellers,Carlos Garcia-Echeverria +16 more
TL;DR: The preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties, and the compound was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.
Journal ArticleDOI
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira,Sabina Pecchi,Alan Huang,Matthew Burger,Mark Knapp,Dario Sterker,Christian Schnell,Daniel Guthy,Tobi Nagel,Marion Wiesmann,Saskia M. Brachmann,Christine Fritsch,Marion Dorsch,Patrick Chène,Kevin Shoemaker,Alain De Pover,Daniel Menezes,Georg Martiny-Baron,Doriano Fabbro,Christine D. Wilson,Robert Schlegel,Francesco Hofmann,Carlos Garcia-Echeverria,William R. Sellers,Charles Voliva +24 more
TL;DR: The biologic characterization of the 2-morpholino pyrimidine derivative pan-PI3K inhibitor NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models and behaves synergistically when combined with either targeted agentssuch as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.
Journal ArticleDOI
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Christine Fritsch,Alan Huang,Christian Chatenay-Rivauday,Christian Schnell,Anupama Reddy,Manway Liu,Audrey Kauffmann,Daniel Guthy,Dirk Erdmann,Alain De Pover,Pascal Furet,Hui Gao,Stephane Ferretti,Youzhen Wang,Joerg Trappe,Saskia M. Brachmann,Sauveur-Michel Maira,Christine D. Wilson,Markus Boehm,Carlos Garcia-Echeverria,Patrick Chène,Marion Wiesmann,Robert Cozens,Joseph Lehar,Robert Schlegel,Giorgio Caravatti,Francesco Hofmann,William R. Sellers +27 more
TL;DR: The biologic properties of the 2-aminothiazole derivative NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms, are reported and it is found that PIK3CA mutation was the foremost positive predictor of sensitivity while revealing additional positive and negative associations such as Pik3CA amplification and PTEN mutation, respectively.
Journal ArticleDOI
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Pascal Furet,Vito Guagnano,Robin Alec Fairhurst,Patricia Imbach-Weese,Ian N. Bruce,Mark Knapp,Christine Fritsch,Francesca Blasco,Joachim Blanz,Reiner Aichholz,Jacques Hamon,Doriano Fabbro,Giorgio Caravatti +12 more
TL;DR: A medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719, a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3Kα.
Journal ArticleDOI
Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
Rami Rahal,Mareike Frick,Rodrigo Romero,Joshua M. Korn,Robert Kridel,Fong Chun Chan,Barbara Meissner,Hyo-eun C. Bhang,Dave Ruddy,Audrey Kauffmann,Ali Farsidjani,Adnan Derti,Daniel P. Rakiec,Tara L. Naylor,Estelle Pfister,Steve Kovats,Sunkyu Kim,Kerstin Dietze,Bernd Dörken,Christian Steidl,Alexandar Tzankov,Michael Hummel,John Monahan,Michael Morrissey,Christine Fritsch,William R. Sellers,Vesselina G. Cooke,Randy D. Gascoyne,Georg Lenz,Frank Stegmeier +29 more
TL;DR: It is revealed that NIK is a new therapeutic target for MCL treatment, particularly for lymphomas that are refractory to BCR pathway inhibitors and provide critical insights into patient stratification strategies for NF-κB pathway–targeted agents.